the ischemia-reperfusion injury of the transplanted kidney
Conditions
Interventions
Experimental group:Intravenous injection of EPO (300 IU/kg)
Control group:Intravenous injection of normal saline 5 mL
Sponsors
The Second Xiangya Hospital of the Central South University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-60 years; 2. 18 kg/m2 < BMI < 28 kg/m2; 3. End-stage renal disease caused by chronic glomerulonephritis; 4. Patients receiving brain dead donor kidney transplantation; 5. Pleco complex gene was detected as heterozygous; 6. High compliance.
Exclusion criteria
Exclusion criteria: 1. ESRD caused by secondary diseases, such as hypertension and diabetes; 2. There are local or systemic infections of the lung, urogenital tract, etc.; 3. Hemoglobin greater than 130 g/L and less than 80 g/L; 4. For poorly controlled hypertension, the systolic blood pressure was still greater than 160 mmHg and the diastolic blood pressure was greater than 100 mmHg after oral administration of antihypertensive drugs; 5. Previous history of thromboembolism (cerebral infarction, pulmonary embolism and other deep vein thrombosis); 6. Severe hypercoagulability or other diseases of the blood system; 7. High risk of cardiovascular and cerebrovascular diseases (acute coronary syndrome in the past 6 months); 8. History of malignant tumor in recent two years; 9. Other conditions that are not suitable for participating in this subject (such as pregnancy, mental illness, etc.).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Glomerular filtration rate, eGFR;T cells and their subsets by flow cytometry; | — |
Secondary
| Measure | Time frame |
|---|---|
| Length of stay in hospital;Delayed graft function;Hemoglobin concentration;C-reactive protein;Urea nitrogen;Serum creatinine;Creatinine clearance;Renal injury index; | — |
Countries
China
Contacts
Public ContactZheng Dong; Xubiao Xie
Kexing Biopharmaceutical Co., Ltd.
Outcome results
None listed